Effectiveness of Non-invasive Ventilation in patients with asthma

Investigation of Non-invasive Positive Pressure Ventilation in patients with moderate to severe acute exacerbation of asthma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017021427929N4

Enrollment

Registered

2017-03-27

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma. Acute severe asthma

Interventions

Intervention 1: In the intervention group: non-invasive ventilation is performed via a face mask with an inspiratory pressure equal to 12 cm H2O and an expiratory pressure equal to 4 cm H2O for 120

Treatment - Devices

In the intervention group: non-invasive ventilation is performed via a face mask with an inspiratory pressure equal to 12 cm H2O and an expiratory pressure equal to 4 cm H2O for 120 minutes. Non-inv

In the control group, a non-invasive device with a face mask without inspiratory and expiratory pressures is placed on the patients faces for 120 minutes.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18-75 years; dyspnea; peak expiratory flow 24/minute; confirmed diagnosis of asthma; receiving standard asthma treatment. Exclusion criteria: Chronic obstructive pulmonary disease; unstable vital signs such as systolic blood pressure <90 mmHg after liquid therapy; patient unwillingness to participate in the study; decrease in level of consciousness; acute myocardial infarction or ischemic heart failure; pH<7.10; unable to use mask; inability to clean airway secretions.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Forced expiatory volume in 1st second. Timepoint: Before and after intervention. Method of measurement: spirometry.	—

Secondary

Measure	Time frame
Arterial PO2. Timepoint: Before and after intervention. Method of measurement: arterial blood gas.;Arterial PCO2. Timepoint: Before and after intervention. Method of measurement: arterial blood gas.;Blood pressure. Timepoint: Before and after intervention. Method of measurement: Clinical counting.;Heart rate. Timepoint: Before and after intervention. Method of measurement: Clinical counting.;Dyspnea. Timepoint: Before and after intervention. Method of measurement: Dyspnea Borg Scale.	—

Measure

Time frame

Arterial PO2. Timepoint: Before and after intervention. Method of measurement: arterial blood gas.;Arterial PCO2. Timepoint: Before and after intervention. Method of measurement: arterial blood gas.;Blood pressure. Timepoint: Before and after intervention. Method of measurement: Clinical counting.;Heart rate. Timepoint: Before and after intervention. Method of measurement: Clinical counting.;Dyspnea. Timepoint: Before and after intervention. Method of measurement: Dyspnea Borg Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Atefeh Fakharian

National Research Institute of Tuberculosis and Lung Diseases

fakharian_2005@yahoo.com+98 21 2610 5050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026